In contrast, the caspase-3/M30 ratio of the tumours correlated very strongly with the disease-free survival of the patients (Figure 2G), with a high ratio (>median) having a significantly better median disease-free survival of 45 vs 26.5 months for the patients with tumours with a low ratio. The gene discussed is CASP3; the disease is neoplasm.